Literature DB >> 17980169

Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis.

Johannes H M Levels1, Dasja Pajkrt, Marcus Schultz, Frans J Hoek, Arie van Tol, Joost C M Meijers, Sander J H van Deventer.   

Abstract

Cell wall constituents of bacteria are potent endotoxins initiating inflammatory responses which may cause dramatic changes in lipid metabolism during the acute phase response. In this study, the sequential changes in lipoprotein composition and lipid transfer and binding proteins during clinical sepsis and during low-dose experimental endotoxemia were followed. In addition, the effect on (phospho)lipid homeostasis by administration of reconstituted HDL (rHDL) prior to low-dose LPS administration was investigated. Changes in (apo)lipoprotein concentrations typical of the acute phase response were observed during clinical sepsis and experimental endotoxemia with and without the rHDL intervention. During clinical sepsis negative correlations between the acute phase marker C-reactive protein (CRP) and lecithin:cholesterol acyltransferase (LCAT) and cholesterylester transfer protein (CETP) activities were seen, whereas positive correlations between plasma phospholipid transfer protein (PLTP) activity and acute phase markers such as CRP and LPS binding protein were observed. Plasma lipid changes upon rHDL/LPS infusion were comparable with the control group (low-dose LPS only). PLTP activity decreased upon LPS infusion and transiently increased during rHDL infusion, whereas LCAT activity slightly decreased upon both LPS infusion and LPS/rHDL infusion. However, long-lasting increases of circulating HDL cholesterol, apo A-I and a high initial processing of both phosphatidylcholine (PC) and lyso-PC, were indicative for extensive rHDL and LDL remodelling. Both sepsis and experimental endotoxemia lead to a disbalance of lipid homeostasis. Depending on the magnitude of the inflammatory stimulus, LCAT and PLTP activities reacted in divergent ways. rHDL infusion did not prevent the lipid alterations seen during the acute phase response. However profound changes in both HDL and LDL phospholipid composition occurred upon rHDL infusion. This may be explained, at least in part, by the fact that PLTP as a positive acute phase protein, can accelerate the alterations in (phospho)lipid homeostasis thereby playing a role in the attenuation of the acute phase response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17980169     DOI: 10.1016/j.bbalip.2007.10.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  33 in total

1.  Blood lipids, infection, and inflammatory markers in the Tsimane of Bolivia.

Authors:  Sarinnapha Vasunilashorn; Eileen M Crimmins; Jung Ki Kim; Jeff Winking; Michael Gurven; Hillard Kaplan; Caleb E Finch
Journal:  Am J Hum Biol       Date:  2010 Nov-Dec       Impact factor: 1.937

2.  Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.

Authors:  John S Millar; Katsunori Ikewaki; LeAnne T Bloedon; Megan L Wolfe; Philippe O Szapary; Daniel J Rader
Journal:  J Lipid Res       Date:  2010-10-22       Impact factor: 5.922

Review 3.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

4.  Plasma Phospholipid Transfer Protein Promotes Platelet Aggregation.

Authors:  Xiao-Min Zhao; Yun Wang; Yang Yu; Hui Jiang; Anna Babinska; Xiu-Yu Chen; Ke-Gui He; Xiang-Dong Min; Ji-Ju Han; Chen-Xi Yang; Kevin Deng; Jing Xue; Xiangjian Zhang; Guo-Hua Song; Shu-Cun Qin; Xian-Cheng Jiang
Journal:  Thromb Haemost       Date:  2018-11-12       Impact factor: 5.249

5.  LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients.

Authors:  Auguste Dargent; Jean-Paul Pais de Barros; Samir Saheb; Randa Bittar; Wilfried Le Goff; Alain Carrié; Thomas Gautier; Isabelle Fournel; Anne Laure Rerole; Hélène Choubley; David Masson; Laurent Lagrost; Jean-Pierre Quenot
Journal:  J Lipid Res       Date:  2020-10-09       Impact factor: 5.922

6.  Inflammation modulates human HDL composition and function in vivo.

Authors:  Margarita de la Llera Moya; Fiona C McGillicuddy; Christine C Hinkle; Michael Byrne; Michelle R Joshi; Vihn Nguyen; Jennifer Tabita-Martinez; Megan L Wolfe; Karen Badellino; Leticia Pruscino; Nehal N Mehta; Bela F Asztalos; Muredach P Reilly
Journal:  Atherosclerosis       Date:  2012-02-28       Impact factor: 5.162

Review 7.  Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases.

Authors:  Parth N Patel; Rhia Y Shah; Jane F Ferguson; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-12-30       Impact factor: 8.311

8.  HDL in humans with cardiovascular disease exhibits a proteomic signature.

Authors:  Tomás Vaisar; Philip Mayer; Erik Nilsson; Xue-Qiao Zhao; Robert Knopp; Bryan J Prazen
Journal:  Clin Chim Acta       Date:  2010-03-20       Impact factor: 3.786

9.  Inflammation impairs reverse cholesterol transport in vivo.

Authors:  Fiona C McGillicuddy; Margarita de la Llera Moya; Christine C Hinkle; Michelle R Joshi; Elise H Chiquoine; Jeffrey T Billheimer; George H Rothblat; Muredach P Reilly
Journal:  Circulation       Date:  2009-02-16       Impact factor: 29.690

10.  Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux.

Authors:  Carlos L J Vrins; Astrid E van der Velde; Karin van den Oever; Johannes H M Levels; Stephane Huet; Ronald P J Oude Elferink; Folkert Kuipers; Albert K Groen
Journal:  J Lipid Res       Date:  2009-05-13       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.